Q-omics provides the consensus-scored NPIPB5 profile across patient tissues and cancer cell-line models. NPIPB5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NPIPB5 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, NPIPB5 RNA expression shows 17,660 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where NPIPB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPIPB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPIPB5 survival associations across molecular data types. NPIPB5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPIPB5 RNA expression–survival associations across cancer types. High NPIPB5 expression shows unfavorable associations in KIRC and COAD, but favorable associations in BLCA, HNSC, SKCM and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NPIPB5 RNA expression.
This table summarizes NPIPB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NPIPB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPIPB5 shows lower tumor expression in BRCA and higher tumor expression in COAD, HNSC, KIRC, LIHC and KIRP. The COAD box plot shows higher NPIPB5 RNA expression in tumor versus normal tissue (log2 FC = +1.036, t-test p < 0.001).
This table shows molecular features associated with NPIPB5 in patient tissues and cancer cell lines. In patient samples, NPIPB5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPIPB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
